← Leaderboards
Nobuyuki Matoba
Arizona State University-Tempe Campus
$6,848,473
Attributed
$7,116,741
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $983.8K · FY2007–25$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,116,741 · 8
By mechanism
U19$2,282,071 · 1
R01$1,831,601 · 1
R21$1,566,109 · 4
R33$1,289,334 · 1
R03$147,626 · 1
Top collaborators
- Haixun Guo1 shared
- Sucheta Telang1 shared
Most similar at Arizona State University-Tempe Campus
Same institution · by research overlap
- Abhinav Acharya$3,362,178
- Sarah E Stabenfeldt$5,832,070
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsBiochemicalProteinsBaseAffinityImmuneIn VitroPlantsBiologicalSafetyAntibodiesViralPharmaceutical PreparationsMonitorImmunohistochemistryHiv-1MolecularMucous MembraneSeriesEnzyme-Linked Immunosorbent AssayMouse ModelHigh Pressure Liquid ChromatographyImmunogenicityBinding
Grant awards (22)
Lectikines for Immunotherapy against Ovarian Cancer$216,987
R21 · FY2025 · CA · contact PI
Lectikines for Immunotherapy against Ovarian Cancer$180,478
R21 · FY2024 · CA · contact PI
Preclinical validation of oral therapeutic lead proteins targeting epithelial GM1 ganglioside for ulcerative colitis therapy$445,661
R01 · FY2023 · DK · contact PI
Antitumor potential of AvFc lectibody in non-small cell lung cancer$402,402
R21 · FY2023 · CA · contact PI
Preclinical validation of oral therapeutic lead proteins targeting epithelial GM1 ganglioside for ulcerative colitis therapy$443,196
R01 · FY2022 · DK · contact PI
Preclinical validation of oral therapeutic lead proteins targeting epithelial GM1 ganglioside for ulcerative colitis therapy$481,444
R01 · FY2021 · DK · contact PI
Preclinical validation of oral therapeutic lead proteins targeting epithelial GM1 ganglioside for ulcerative colitis therapy$461,300
R01 · FY2020 · DK · contact PI
Investigation of a lectibody targeting tumor-associated oligomannose glycans$193,023
R21 · FY2019 · CA · contact PI
Core C: PREVENT Program Pharmacokinetics and Pharmacodynamics Services Core$469,831
U19 · FY2018 · AI · contact PI
Investigation of a lectibody targeting tumor-associated oligomannose glycans$165,555
R21 · FY2018 · CA · contact PI
Core C: PREVENT Program Pharmacokinetics and Pharmacodynamics Services Core$238,764
U19 · FY2017 · AI · contact PI
Core C: PREVENT Program Pharmacokinetics and Pharmacodynamics Services Core$465,401
U19 · FY2016 · AI · contact PI
Core C: PREVENT Program Pharmacokinetics and Pharmacodynamics Services Core$556,347
U19 · FY2015 · AI · contact PI
Core C: PREVENT Program Pharmacokinetics and Pharmacodynamics Services Core$551,728
U19 · FY2014 · AI · contact PI
Plant-produced Actinohivin as a Candidate HIV Microbicide$432,107
R33 · FY2014 · AI · contact PI
Plant-produced Actinohivin as a Candidate HIV Microbicide$408,941
R33 · FY2013 · AI · contact PI
Plant-produced Actinohivin as a Candidate HIV Microbicide$448,286
R33 · FY2012 · AI · contact PI
Plant-produced Actinohivin as a Candidate HIV Microbicide$206,514
R21 · FY2011 · AI · contact PI
Plant-produced Actinohivin as a Candidate HIV Microbicide$201,150
R21 · FY2010 · AI · contact PI
Expression of Decontructed HIV-1 Virus-Like Particles in Bioengineered Plants$44,769
R03 · FY2008 · AI · contact PI
Expression of Decontructed HIV-1 Virus-Like Particles in Bioengineered Plants$28,107
R03 · FY2008 · AI · contact PI
Expression of Decontructed HIV-1 Virus-Like Particles in Bioengineered Plants$74,750
R03 · FY2007 · AI · contact PI